Background. Podocytes play an important role in maintaining normal glomerular function. A podocyte-specific conditional knockout technology has been established by the use of transgenic mice expressing a podocyte-specific Cre recombinase to clarify the role of genes expressed in the podocytes. However, it may be difficult to examine the role of genes in certain pathologic conditions using conventional podocyte-specific knockout mice because they may be embryonically lethal or exhibit congenital renal abnormality. Methods. To introduce a temporal control in the genetic experiments targeting the podocyte, we constructed tamoxifen-inducible Cre recombinase (CreER T2 ) transgenic mice under the control of podocyte-specific promoter, 2.5-kb fragment of the human podocin (NPHS2) gene. The specificity and efficiency of Cre activity were examined by crossing NPHS2-CreER T2 with the ROSA26 reporter (R26R) mouse in which a floxed-stop cassette has been placed upstream of the β-galactosidase gene. Four-weekold double-mutant mice (NPHS2-CreER T2 /R26R) were intraperitoneally administered with 0.5 mg of 4-hydroxytamoxifen (4-OHT) for three consecutive days. Results. NPHS2-CreER T2 /R26R treated with 4-OHT expressed β-galactosidase specifically in 85% of the podocytes in glomeruli. Expression of Cre recombinase mRNA was mostly restricted to the kidney, especially in glomeruli.
Introduction
Podocytes are highly differentiated cells that form multiple interdigitating foot processes [1] . The podocytes contribute to the specific size and charge filtration barrier, and their damage leads to proteinuria and kidney injury [1] . Nephrin, the NPHS1 gene product, is identified as a responsible protein for congenital nephrotic syndrome of the Finnish type [2] . The human and murine nephrin promoter drives the podocyte expression in the kidney [3, 4] . Betagalactosidase activity is also detected in the brain and pancreas other than the podocytes in 5.4-or 8.3-kb murine Nphs1 promoter-driven LacZ transgenic mice [3, 5] . On the other hand, a 1.25-kb human or murine nephrin promoter can drive the podocyte-specific LacZ expression [4, 5] . Podocin, coded by the NPHS2 gene, is also identified as a causative gene responsible for a familial form of early-onset nephrotic syndrome [6] . Podocin promoter, a 2.5-kb human NPHS2 promoter, has been used to drive the podocyte-specific transgene expression [5, 7] . NPHS2 promoter-driven LacZ transgenic mice showed a better penetrance than NPHS1-LacZ transgenic mice [5] . An inducible podocyte-specific gene expression has been demonstrated previously [8, 9] , and this inducible procedure has been used to construct inducible knockout mice.
The Cre/loxP system is widely used to excise the gene segment flanked by loxP recognition sequences (floxed) [10] . This technology has been used for conditional knockout mice. In the kidney, podocyte-specific Cre transgenic mice are generated for podocyte-specific gene deletion [7, 11] . Although the podocyte-specific conditional knockout mice are useful in investigating the role of the gene, several podocyte-specific knockout mice exhibit congenital renal abnormalities and perinatal death [12] , which is caused by the disruption of the gene in the embryonic kidney stage. This strategy often has difficulty in elucidating the role of the gene in the diseased or postnatal kidney.
Recently, efforts have been undertaken to create a temporal regulation for Cre recombination [13] . The two major induction systems are tetracycline and tamoxifen. Podocytespecific tetracycline-inducible Cre transgenic mice have been generated [14] [15] [16] . These mice can excise the floxed gene exclusively in the podocytes with temporal regulation. Another inducible Cre transgenic mice system is based on the fusion protein of Cre recombinase and mutant oestrogen receptor (CreER T2 ), which is highly sensitive to 4-hydroxytamoxifen (4-OHT) but not to oestrogen [17, 18] . Although tamoxifen-inducible mice under pCAGGS plasmid, containing cytomegalovirus enhancer chicken β-actin promoter and polyadenylation signal, have been shown to direct gene recombination in podocytes and other tissues [9] , the podocyte-specific tamoxifen-inducible Cre recombinase mice was not constructed. We generated CreER T2 transgenic mice under the control of the 2.5-kb human NPHS2 promoter.
Materials and methods

Generation of NPHS2-CreER T2 mice
The SacII site of pExchangeI vector (Stratagene, La Jolla, CA, USA) was blunted and ligated with MluI-linker. The plasmid pCreER T2 (a kind gift from Professor P. Chambon) was digested with EcoRI, and the 2.0-kb fragment of pCreER T2 was subcloned into EcoRI site of pExchangeI-MluI vector. A bacterial artificial chromosome (BAC) clone, RP11-231PS, containing human NPHS2 gene was purchased from Invitrogen (Casrlsbad, CA, USA). The 2.5-kb promoter of the human NPHS2 was PCR amplified using the following primers: 5'-CTATTTAGTCTCTCTGCCACC-3' and 5'-TCCTCAGAGCTGCCGGGCGGC-3' [5] . The PCR product was subcloned into pGEM-T-Easy vector (Promega, Madison, MI, USA), and the nucleotide sequence was confirmed. A 2.5-kb NotI fragment of the pGEM-T-Easy-human NPHS2 promoter was inserted into the pExchangeI-MluI-CreER T2 . The MluI fragment of the fusion gene was used to generate C57BL/6J background transgenic mice. PCR was performed using tail tissue DNA with following primers specific for Cre recombinase: 5'-GCAAGAACCTGATGGACA-3' and 5'-CTAGAG-CCTGTTTTGCAC-3'. DNA from transgenic mice gave a 336-bp PCR product.
Administration of 4-hydroxytamoxifen and LacZ staining
All animal experiments were approved by the Animal Experimentation Committee of Kyoto University Graduate School of Medicine. The ROSA26 reporter (R26R) mice were purchased from the Jackson Laboratory (Bar Harbor, ME, USA), in which a floxed-stop cassette has been placed upstream of the β-galactosidase gene. Ten milligrams 4-hydroxytamoxifen (4-OHT; Sigma-Aldrich, St Louis, MO, USA) was dissolved in 100 μl ethanol, and further diluted with autoclaved sunflower oil (SigmaAldrich) with sonication to obtain 10 mg/ml 4-OHT solution [18] . To test the Cre-mediated postnatal recombination, 4-week old NPHS2-CreER T2 / R26R mice were intraperitoneally administered with 0.5 mg of 4-OHT for one or three consecutive days. At 6 or 24 hours after one injection, the kidneys were fixed with LacZ fixation solution containing 0.2% glutaraldehyde, 5 mM EGTA pH 7.3, 100 mM MgCl 2 in 100 mM PBS for 4 h at 4°C with shaking. The kidneys were also harvested 24 or 168 h after the final of three consecutive injections. Kidney sections were stained using β-galactosidase staining kit (Invitrogen) for 24 h at 30°C. In control mice, only autoclaved sunflower oil was administered. Immunofluorescence study for β-galactosidase (Millipore, Billerica, MA, USA) and nephrin (R&D Systems, Minneapolis, MN, USA) were performed as described (n = 3) [19] . The slides were developed by a fluorescence microscopy (IX-81; Olympus, Tokyo, Japan, and BZ-9000; Keyence, Osaka, Japan). The positive area for nephrin and the double-positive area for β-galactosidase and nephrin were quantitatively measured in 10 glomeruli using a computer-aided manipulator (MetaMorph; Molecular Devices, Downingtown, PA, USA).
Real-time RT-PCR
A quantitative real-time RT-PCR was performed as previously described [19] . Tissues were homogenized, and then, total RNA was extracted (n = 3). The glomeruli were isolated from NPHS2-CreER T2 mice using differential sieving method. Primers and probe for Cre recombinase were as follows: Cre forward, 5'-GCCACGACCAAGTGACAGC-3', Cre reverse, 5'-TGCACGTTCACCGGCATC-3', Cre probe, 5'-FAM- . Transgenic mice (Tg) showed a 336-bp positive band, and wild-type mice (WT) showed no band.
Podocyte-specific CreER T2 mice 2121 TCCGCCGCACAACCAGTGAAACAGC-TAMRA-3'. GAPDH expression was used as an internal control, and data were analysed by the relative quantification (ΔΔC T ) method.
Results
Generation of podocyte-specific tamoxifen-inducible CreER T2 transgenic mice
We constructed the transgenic mice using a fragment of the human podocin gene (NPHS2) promoter, Cre recombinase fused with mutated ligand-binding domain of the human oestrogen receptor (CreER T2 ) and polyA signal ( Figure 1A ). Transgenic founder lines carrying the human NPHS2 promoter-CreER T2 transgene were identified by PCR analysis ( Figure 1B) . We obtained three founders of NPHS2-CreER T2 transgenic mice (NPHS2-CreER
T2
). All NPHS2-CreER T2 were fertile, grew normally and showed normal gross appearance, including kidney size and renal histology.
Cre-mediated recombination
To determine the ability of Cre recombinase on tamoxifeninducible selective recombination of loxP sites, we crossbred NPHS2-CreER T2 with the R26R mouse line, which carries a floxed-stop cassette located upstream of the β-galactosidase gene. Thus, R26R express β-galactosidase after Cre-mediated incision. Four-week-old double-mutant mice (NPHS2-CreER T2 / R26R) were administered with 4-hydroxytamoxifen (4-OHT) to induce a Cre-mediated recombination. At 6 h after the injection of 4-OHT, the kidney showed no β-galactosidase staining. Beta-galactosidase expression was gradually increased at 24 h after one injection, and became strong on the following day after the third injection (72 h). At 7 days after the final 4-OHT administration (216 h), the β-galactosidase expression was detected in the glomeruli and in the peripheral cells in each glomerulus with X-gal staining ( Figure 2B ), which showed a characteristic peripheral distribution consistent with podocytes. Three out of three NPHS2-CreER T2 transgenic founder lines were positive for X-gal staining. On the other hand, no β-galactosidase activity was observed in NPHS2-CreER T2 /R26R without 4-OHT administration ( Figure 2B ). There was no staining in the brain, lung, heart, liver, spleen and pancreas (data not shown). The real-time RT-PCR analysis showed that the Cre recombinase expression was mostly restricted in the kidney, especially in the glomeruli (Figure 3 ). To confirm that β-galactosidase-positive cells were podocytes, double-immunofluorescent analyses for β-galactosidase and nephrin were performed. In the NPHS2-CreER T2 / R26R kidneys treated with 4-OHT, immunofluorescent study showed that the β-galactosidase-positive cells were also positive for nephrin, indicating that this recombination was specif ic to the podocytes ( Figure 4A-C) . Eighty-five percent of the nephrin staining area was also positive for β-galactosidase by double-immunofluorescent analyses.
Discussion
Podocytes are highly differentiated cells that play an important role as a glomerular barrier [1] . To evaluate the role of proteins existing in podocytes, podocyte-specific knockout mice have been generated by crossbreeding the podocyte-specific Cre recombinase transgenic mice with floxed mice [12, 20] . The podocyte-specific transgenic mice have been generated by using nephrin and podocin promoter [3] [4] [5] 8, 19, 21] . Human NPHS2 promoter is shown to be a podocyte-specific promoter [5] . A penetrance of LacZ transgene driven by the human NPHS2 promoter has been shown to be better than human NPHS1 promoter-driven LacZ transgenic mice [6] . In this study, we use NPHS2 promoter to express tamoxifen-inducible Cre recombinase. The 2.5-kb fragment of human NPHS2 promoter-driven tamoxifen-inducible Cre recombinase transgenic mice (NPHS2-CreER T2 ) shows a podocyte-specific expression. No β-galactosidase staining is detected in other organs. The penetrance of founder lines in NPHS2-CreER T2 is 100%, and the recombination efficacy of the podocytes is 85% in each glomerulus in 4-week-old mice. The β-galactosidase activity is not detected without 4-OHT administration in NPHS2-CreER T2 . Although several lines of podocyte-specific knockout mice have been constructed, this system does not necessarily elucidate the role of the genes in the postnatal or diseased kidney because of the deletion of genes causing perinatal death and major abnormalities. Use of temporal-regulated Cre transgenic mice is one option in investigating the role of the gene in the postnatal or diseased organs [13] . The two major induction systems are tetracycline and tamoxifen. Podocyte-specific tetracycline-inducible Cre transgenic mice are constructed using NPHS2 promoter [14, 15] . In the present study, we employ a tamoxifen system. The tamoxifen-inducible system has a benefit in fewer independent transgenes, resulting in a fewer breedings and fewer genotyping procedures [14] . In Fig. 3 . Real-time RT-PCR analysis of Cre recombinase mRNA. Cre recombinase mRNA expression was analysed in the brain, heart, lung, liver, pancreas, spleen, stomach, whole kidneys and glomeruli (n = 3). Cre recombinase expression was mostly restricted in the kidney, especially in glomeruli. **P < 0.01 vs. brain, heart, lung, liver, pancreas, spleen and stomach. Podocyte-specific CreER T2 micecontrast, the tamoxifen system presents a considerable limitation in embryonic deletion. The dose of tamoxifen required to activate the fusion protein of Cre recombinase and muted oestrogen receptor (CreER TM ) has been shown quite close to that which interferes with the maintenance of pregnancy [22] . In addition, tamoxifen itself has teratogenicity in rodents [23] . We construct the podocyte-specific tamoxifen-inducible Cre transgenic mice by using fusion protein of Cre recombinase and mutated oestrogen receptor (CreER  T2 ) . CreER T2 has a high affinity for 4-OHT [17] , and NPHS2-CreER T2 mice can delete floxed genes as early as 24h after 4-OHT administration. No paper reported the comparison between the tetracycline and tamoxifen systems in the podocyte-specific inducible Cre mice. It requires further clarification to compare merits and demerits between the tamoxifen and tetracycline systems in the podocyte-specific inducible Cre recombinase mice.
In summary, we constructed the podocyte-specific promoter-driven CreER T2 transgenic mice, and showed that NPHS2-CreER T2 can effectively cause a recombination of the genes in podocytes. These mice can be used for a temporally regulated podocyte-specific gene deletion.
